Your proposal in few words
Approxima is a spin-off of the Politecnico di Milano founded in 2020. Its mission is to develop a new implantable medical device for the minimally invasive treatment of tricuspid and right heart failure. There are 4M patients in the world suffering from these diseases that are today considered inoperable, Approxima aims to meet this emerging and as yet unresolved medical need.
What is your main purpose and the idea behind it?
The idea is the result of a collaboration between engineers from the Milan Polytechnic and heart surgeons from the Luigi Sacco Hospital and is based on the application of new clinical, scientific and technological knowledge. The Approxima device is the only one capable of counteracting ventricular dilation, the cause of tricuspid and right heart failure. Functional prototypes of the device have been developed and tested in an ex-vivo environment (TRL 3/4), and the technology is protected by national patent and PCT applications. We expect to carry out the first in-vivo (animal) pilot test by 2021, the implementation of clinical units of the device by 2022, their pre-clinical validation by 2024 and the achievement of our main goal: human pilot testing by 2025. The emerging market opens up great opportunities for future collaborations with corporate partners.
How does the Startup Breeding experience help you in the growth and development of your business
Participation in SUB2021 gives us the opportunity to work together with an expert in the field of cardiovascular medical devices. We believe the mentoring sessions are a great opportunity to review and refine our startup’s value proposition, roadmap and business model, while improving our presentation for the final event. The programme also allows us to extend our network, broaden our market-fit validation and present the project to new potential investors.
Linkedin:
